Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.61% | 47.67% | 55.54% | 42.55% | 53.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.61% | 47.67% | 55.54% | 42.55% | 53.87% |
| Cost of Revenue | 30.75% | 33.50% | 60.76% | 40.28% | 38.57% |
| Gross Profit | 40.23% | 50.31% | 54.44% | 43.04% | 57.45% |
| SG&A Expenses | 14.01% | 24.59% | 18.88% | 24.79% | 38.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.68% | 23.19% | 34.93% | 29.69% | 33.76% |
| Operating Income | 56.12% | 77.42% | 84.42% | 62.32% | 84.32% |
| Income Before Tax | 16.22% | 36.45% | 156.08% | 64.07% | 355.36% |
| Income Tax Expenses | 18.48% | 92.83% | 108.61% | 159.11% | 166.95% |
| Earnings from Continuing Operations | 15.55% | 25.33% | 168.07% | 50.52% | 475.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.55% | 25.33% | 168.07% | 50.52% | 475.39% |
| EBIT | 56.12% | 77.42% | 84.42% | 62.32% | 84.32% |
| EBITDA | 53.99% | 73.24% | 78.44% | 58.85% | 76.53% |
| EPS Basic | 16.19% | 26.10% | 169.33% | 51.39% | 478.03% |
| Normalized Basic EPS | 57.04% | 84.74% | 92.74% | 61.39% | 89.14% |
| EPS Diluted | 16.26% | 26.23% | 169.93% | 51.39% | 480.37% |
| Normalized Diluted EPS | 57.11% | 84.86% | 92.85% | 61.39% | 89.58% |
| Average Basic Shares Outstanding | -0.56% | -0.61% | -0.47% | -0.57% | -0.46% |
| Average Diluted Shares Outstanding | -0.60% | -0.68% | -0.52% | -0.57% | -0.69% |
| Dividend Per Share | 15.33% | 15.33% | 15.33% | 15.38% | 15.38% |
| Payout Ratio | -0.01% | -0.08% | -0.57% | -0.23% | -0.80% |